Beneficial effect of TNF-α inhibition on diabetic peripheral neuropathy

Journal of Neuroinflammation

Volumn 10, Issue , 2013, Pages

  Shi, Xiaohong ^a   Chen, Yinghui ^a   Nadeem, Lubna ^b   Xu, Guoxiong ^a  

^a FUDAN UNIVERSITY   (China)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Cytokine; Diabetes; Myelin basic protein; Nerve conduction velocity; rhTNFR:Fc; TNF

Indexed keywords

HYBRID PROTEIN; MYELIN BASIC PROTEIN; RECOMBINANT PROTEIN; STREPTOZOCIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEMYELINATION; DIABETIC NEUROPATHY; ENZYME INHIBITION; HISTOLOGY; HISTOPATHOLOGY; LAMELLAR BODY; LIPID DIET; MALE; NERVE CONDUCTION; NERVE INJURY; NERVOUS TISSUE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SCIATIC NERVE; SIGNAL TRANSDUCTION; SUGAR INTAKE; TREATMENT OUTCOME;

EID: 84878407822     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-10-69     Document Type: Article

References (26)

1. Wooten K. Clinical features and electrodiagnosis of diabetic peripheral neuropathy in the dysvascular patient. Phys Med Rehabil Clin N Am 2009, 20:657-676. 10.1016/j.pmr.2009.06.011, 19781504.
2. Tesfaye S, Selvarajah D. Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes Metab Res Rev 2012, 28(Suppl 1):8-14.
3. Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005, 28:956-962. 10.2337/diacare.28.4.956, 15793206.
4. Krendel DA, Costigan DA, Hopkins LC. Successful treatment of neuropathies in patients with diabetes mellitus. Arch Neurol 1995, 52:1053-1061. 10.1001/archneur.1995.00540350039015, 7487556.
5. Wang Y, Schmeichel AM, Iida H, Schmelzer JD, Low PA. Enhanced inflammatory response via activation of NF-kappaB in acute experimental diabetic neuropathy subjected to ischemia-reperfusion injury. J Neurol Sci 2006, 247:47-52. 10.1016/j.jns.2006.03.011, 16631800.
6. Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, Stehouwer CD. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes-the EURODIAB Prospective Complications Study. Diabetologia 2005, 48:370-378. 10.1007/s00125-004-1628-8, 15692810.
7. Satoh J, Yagihashi S, Toyota T. The possible role of tumor necrosis factor-alpha in diabetic polyneuropathy. Exp Diabesity Res 2003, 4:65-71. 10.1155/EDR.2003.65, 2478597, 14630568.
8. Zoppini G, Faccini G, Muggeo M, Zenari L, Falezza G, Targher G. Elevated plasma levels of soluble receptors of TNF-alpha and their association with smoking and microvascular complications in young adults with type 1 diabetes. J Clin Endocrinol Metabol 2001, 86:3805-3808.
9. Gonzalez-Clemente JM, Mauricio D, Richart C, Broch M, Caixas A, Megia A, Gimenez-Palop O, Simon I, Martinez-Riquelme A, Gimenez-Perez G, Vendrell J. Diabetic neuropathy is associated with activation of the TNF-alpha system in subjects with type 1 diabetes mellitus. Clin Endocrinol (Oxf) 2005, 63:525-529.
10. Moriwaki Y, Yamamoto T, Shibutani Y, Aoki E, Tsutsumi Z, Takahashi S, Okamura H, Koga M, Fukuchi M, Hada T. Elevated levels of interleukin-18 and tumor necrosis factor-[alpha] in serum of patients with type 2 diabetes mellitus: Relationship with diabetic nephropathy. Metab Clin Exp 2003, 52:605-608. 10.1053/meta.2003.50096, 12759891.
11. Reed MJ, Meszaros K, Entes LJ, Claypool MD, Pinkett JG, Gadbois TM, Reaven GM. A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. Metabolism 2000, 49:1390-1394. 10.1053/meta.2000.17721, 11092499.
12. Harati Y. Diabetic neuropathies: unanswered questions. Neurol Clin 2007, 25:303-317. 10.1016/j.ncl.2007.01.002, 17324729.
13. Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C, Witte DR, Fuller JH. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005, 352:341-350. 10.1056/NEJMoa032782, 15673800.
14. Tavakkoly-Bazzaz J, Amoli MM, Pravica V, Chandrasecaran R, Boulton AJ, Larijani B, Hutchinson IV. VEGF gene polymorphism association with diabetic neuropathy. Mol Biol Rep 2010, 37:3625-3630. 10.1007/s11033-010-0013-6, 20352346.
15. Miranda-Massari JR, Gonzalez MJ, Jimenez FJ, Allende-Vigo MZ, Duconge J. Metabolic correction in the management of diabetic peripheral neuropathy: improving clinical results beyond symptom control. Curr Clin Pharmacol 2011, 6:260-273. 10.2174/157488411798375967, 22082324.
16. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580-591. 10.1056/NEJMoa0706245, 18256393.
17. Said G, Lacroix C, Lozeron P, Ropert A, Plante V, Adams D. Inflammatory vasculopathy in multifocal diabetic neuropathy. Brain 2003, 126:376-385. 10.1093/brain/awg029, 12538404.
18. Gundogdu BM. Diabetic peripheral neuropathy: an update on pathogenesis and management. Curr Neurol Neurosci Rep 2006, 6:1-4.
19. Lappas M, Permezel M, Rice GE. Advanced glycation endproducts mediate pro-inflammatory actions in human gestational tissues via nuclear factor-kappaB and extracellular signal-regulated kinase 1/2. J Endocrinol 2007, 193:269-277. 10.1677/JOE-06-0081, 17470518.
20. Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care 2004, 27:1458-1486. 10.2337/diacare.27.6.1458, 15161806.
21. Sinnreich M, Taylor BV, Dyck PJ. Diabetic neuropathies. Classification, clinical features, and pathophysiological basis. Neurologist 2005, 11:63-79. 10.1097/01.nrl.0000156314.24508.ed, 15733329.
22. Fromont A, De Seze J, Fleury MC, Maillefert JF, Moreau T. Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. Cytokine 2009, 45:55-57. 10.1016/j.cyto.2008.11.002, 19109035.
23. Malik RA, Newrick PG, Sharma AK, Jennings A, Ah-See AK, Mayhew TM, Jakubowski J, Boulton AJ, Ward JD. Microangiopathy in human diabetic neuropathy: relationship between capillary abnormalities and the severity of neuropathy. Diabetologia 1989, 32:92-102. 10.1007/BF00505180, 2721843.
24. Estrella JS, Nelson RN, Sturges BK, Vernau KM, Williams DC, LeCouteur RA, Shelton GD, Mizisin AP. Endoneurial microvascular pathology in feline diabetic neuropathy. Microvasc Res 2008, 75:403-410. 10.1016/j.mvr.2007.12.002, 2413429, 18207200.
25. Dogrul A, Gul H, Yesilyurt O, Ulas UH, Yildiz O. Systemic and spinal administration of etanercept, a tumor necrosis factor alpha inhibitor, blocks tactile allodynia in diabetic mice. Acta Diabetol 2011, 48:135-142. 10.1007/s00592-010-0237-x, 21104419.
26. Zhang C, Cai S, Chen P, Chen JB, Wu J, Wu SJ, Zhou R. Inhibition of tumor necrosis factor-alpha reduces alveolar septal cell apoptosis in passive smoking rats. Chin Med J (Engl) 2008, 121:597-601.